Is Egrifta (Tesamorelin) Legal in Tennessee?

HealthRX.com

Egrifta is FDA-approved, so it is legal with a prescription

1.28 mgOnce-daily dose of Egrifta WR, the 11.6 mg vial formulationSource: dailymed.nlm.nih.gov

Print or save as PDF

Key numbers

  • 47%Share of patients treated for 26 weeks whose IGF-1 rose above 2 SDSSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 1.4 mgOnce-daily dose of Egrifta SV, the 2 mg vial formulation, injected under the skinSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 1.28 mgOnce-daily dose of Egrifta WR, the 11.6 mg vial formulationSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 5%Share of patients on tesamorelin with HbA1c of 6.5% or higher by week 26 (placebo: 1%)Source: dailymed.nlm.nih.gov, as cited Nov 7, 2026

See the public record for Tesamorelin

  • FDA status / Approved prescription drug, BLA 022505, first approved November 10, 2010 [1]
  • Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy [2]
  • Current products / Egrifta SV 1.4 mg and Egrifta WR 1.28 mg, once-daily subcutaneous injections [2][3]
  • Compounding / FDA has made no category-based statement about compounding tesamorelin [4][5][6]
  • Sport / WADA prohibits tesamorelin at all times, in and out of competition [7][8]
  • Not approved for / Weight loss, anti-aging or muscle building [2]

What the FDA approval covers

Tesamorelin is a synthetic analog of human growth hormone-releasing factor (GHRF, also called GHRH): the 44-amino-acid human sequence plus a hexenoyl group on the N-terminal tyrosine [2]. It binds and stimulates GRF receptors on pituitary somatotroph cells, so the pituitary makes and releases more of the body's own growth hormone, which then raises IGF-1 and IGFBP-3 [2]. It is a peptide, not growth hormone and not a steroid [2].

The only approved use is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [2]. The label lists these limits: long-term cardiovascular safety has not been established; the risk and benefit of continuing should be weighed in patients who have not had a reduction in visceral adipose tissue; and the drug is not indicated for weight loss management, which the label describes as a weight-neutral effect. The label also says there are no data that it improves adherence to antiretroviral therapy [2].

Two formulations are currently marketed. Egrifta SV is a 2 mg vial given as 1.4 mg once daily, and Egrifta WR is an 11.6 mg vial given as 1.28 mg once daily; both labels are dated July 29, 2026, and the labels state that the two are not substitutable [2][3].

Compounding: what the federal position says

FDA keeps two lists of bulk drug substances: one for state-licensed pharmacies and physicians (updated May 14, 2026) and one for outsourcing facilities (updated March 21, 2025). Tesamorelin appears in no category on either list, and it is not on FDA's page of bulk substances that may present significant safety risks when compounded (content dated 04/22/2026) [4][5][6]. FDA has therefore made no category-based statement about compounding it [4][5][6]. Tesamorelin is already a component of an FDA-approved product [1].

The HHS draft enforcement-discretion policy for compounded peptides, filed October 28, 2026 (Federal Register document 2026-22192), names six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Tesamorelin is not one of them [9][10].

Compounded drugs are not FDA-approved. FDA does not review their safety, effectiveness or quality before they are marketed [11].

Tennessee

The status described on this page is the federal one: Egrifta is an FDA-approved prescription medicine. The facts here do not address any Tennessee-specific requirements.

Questions worth asking

Choose the questions you want to keep

What the labels list as contraindications and warnings

Contraindications are disruption of the hypothalamic-pituitary axis (for example hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation or head trauma), active malignancy, known hypersensitivity to tesamorelin or the excipients, and pregnancy [2][3]. Both labels also warn about:

  • Neoplasms: tesamorelin raises GH, a growth factor, and the labels say to discontinue if there is evidence of recurrent malignancy [2].
  • Elevated IGF-1: the labels say to monitor IGF-1; among patients treated for 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS [2].
  • Glucose intolerance or diabetes: HbA1c of 6.5% or higher developed in 5% on tesamorelin versus 1% on placebo by week 26, hazard ratio about 3.3 (95% CI 1.4 to 9.6) [2].
  • Fluid retention, hypersensitivity and injection sites: hypersensitivity reactions occurred in 4% of patients in trials, and injection site reactions in 25% on tesamorelin versus 14% on placebo during the first 26 weeks [2].

Athletes

WADA's Prohibited List names tesamorelin under S2.2.4 (growth hormone releasing factors), and it is prohibited at all times, in and out of competition [7]. It is on the 2026 List, in force since January 1, 2026, and remains on the tracked-changes version of the 2027 List dated 26 August 2026 [7][8].

Is Egrifta (tesamorelin) legal in Tennessee?
Egrifta is an FDA-approved prescription drug (BLA 022505, first approved November 10, 2010), so with a valid prescription it is a legal medicine under federal law [1][2].
What is Egrifta approved to treat?
Reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [2]. The label states that long-term cardiovascular safety has not been established, that it is not indicated for weight loss management (weight-neutral effect), and that there are no data showing improved adherence to antiretroviral therapy [2].
Is compounded tesamorelin FDA-approved?
No. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [11]. Tesamorelin appears in no category of FDA's bulk substance lists for state-licensed pharmacies and physicians or for outsourcing facilities, and it is not on FDA's list of substances that may present significant safety risks when compounded [4][5][6].
What dose do the current Egrifta products use?
Egrifta SV is 1.4 mg (0.35 mL of the reconstituted solution) injected subcutaneously into the abdomen once daily, and Egrifta WR is 1.28 mg (0.16 mL of the reconstituted solution) once daily [2][3]. The labels state the two are not substitutable [3].
Can athletes use tesamorelin?
WADA names tesamorelin in S2.2.4 of its Prohibited List and prohibits it at all times, in and out of competition [7]. It is on the 2026 List and remains on the 2027 tracked-changes version [7][8].
What are the main warnings on the Egrifta labels?
Increased risk of neoplasms, elevated IGF-1 (47% of patients treated for 26 weeks had IGF-1 above 2 SDS), glucose intolerance or diabetes (HbA1c of 6.5% or higher in 5% versus 1% on placebo), fluid retention, hypersensitivity reactions (4% in trials) and injection site reactions (25% versus 14% on placebo) [2].
Show all 11 referencesHide references
Evidence overview for Is Egrifta (Tesamorelin) Legal in Tennessee?